ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy
1 Jun 2021 in Clinical and translational allergy, vol. 11
DOI: https://doi.org/10.1002/clt2.12014
Research output: Contribution to Journal › Article (Published)
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines
8 Mar 2021 in Allergy
DOI: https://doi.org/10.1111/all.14809
Research output: Contribution to Journal › Article (Published)
COVID‐19 pandemic and allergen immunotherapy – an EAACI survey
2 Mar 2021 in Allergy
DOI: https://doi.org/10.1111/all.14793
Research output: Contribution to Journal › Article (E-pub ahead of print)
Prostaglandin E2 promotes intestinal inflammation via inhibiting microbiota-dependent regulatory T cells
12 Feb 2021 in Science Advances
DOI: https://doi.org/10.1126/sciadv.abd7954
Research output: Contribution to Journal › Article (Published)
EAACI Biologicals Guidelines—dupilumab for children and adults with moderate‐to‐severe atopic dermatitis
7 Dec 2020 in Allergy
DOI: https://doi.org/10.1111/all.14690
Research output: Contribution to Journal › Article (E-pub ahead of print)